Salarius Pharmaceuticals, Inc. (SLRX)
NASDAQ: SLRX · Real-Time Price · USD
5.77
+0.45 (8.46%)
At close: Aug 22, 2025, 4:00 PM
5.66
-0.11 (-1.91%)
After-hours: Aug 22, 2025, 7:29 PM EDT

Salarius Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202017 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2017 - 2020
----1.845.23
Upgrade
Revenue Growth (YoY)
-----64.84%51.03%
Upgrade
Cost of Revenue
----8.556.91
Upgrade
Gross Profit
-----6.71-1.68
Upgrade
Selling, General & Admin
5.174.965.727.146.16.11
Upgrade
Research & Development
0.50.777.1715.84--
Upgrade
Operating Expenses
5.685.7312.8922.986.16.11
Upgrade
Operating Income
-5.68-5.73-12.89-22.98-12.81-7.79
Upgrade
Interest & Investment Income
0.080.160.350.22--
Upgrade
Other Non Operating Income (Expenses)
---0.010.040.43
Upgrade
EBT Excluding Unusual Items
-5.6-5.58-12.54-22.74-12.77-7.35
Upgrade
Impairment of Goodwill
----8.87--
Upgrade
Pretax Income
-5.1-5.58-12.54-31.61-12.77-7.35
Upgrade
Net Income
-5.1-5.58-12.54-31.61-12.77-7.35
Upgrade
Preferred Dividends & Other Adjustments
-----0.4
Upgrade
Net Income to Common
-5.1-5.58-12.54-31.61-12.77-7.75
Upgrade
Free Cash Flow
-4.14-4.53-12.85-17.6-10.2-10.31
Upgrade
Gross Margin
------32.11%
Upgrade
Operating Margin
-----696.27%-148.78%
Upgrade
Profit Margin
-----693.84%-148.06%
Upgrade
Free Cash Flow Margin
-----554.29%-197.08%
Upgrade
EBITDA
-5.68-5.73-12.88-22.97-12.79-7.77
Upgrade
EBITDA Margin
------148.44%
Upgrade
D&A For EBITDA
000.010.010.020.02
Upgrade
EBIT
-5.68-5.73-12.89-22.98-12.81-7.79
Upgrade
EBIT Margin
------148.78%
Upgrade
Updated Mar 21, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q